Screener
Aclaris Therapeutics ACRS Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
FAQ
- What is Aclaris Therapeutics's total equity?
- Aclaris Therapeutics (ACRS) reported total equity of $124.58M in Q2 2026.
- How has Aclaris Therapeutics's total equity changed year-over-year?
- Aclaris Therapeutics's total equity decreased by 5.4% year-over-year, from $131.74M to $124.58M.
- What is the long-term trend for Aclaris Therapeutics's total equity?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's total equity has grown at a 22.3% compound annual growth rate (CAGR), from $37.65M to $103.08M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Aclaris Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude